180 Life Sciences Corp. (NASDAQ:ATNF) finished Wednesday with an addition of $1.07 to close at $4.24, an upside of 33.75 percent. An average of 5,103,600 shares of common stock have been traded in the last five days. There was a gain of $0.68 in the past week, and it reached a new high 4 times over the past 12 months. The last 20 days have seen an average of 11,236,970 shares traded, while the 50-day average volume stands at 5,255,022.
ATNF stock has increased by 168.35% in the last month. The company shares reached their 1-month lowest point of $1.55 on 12/29/22. With the stock rallying to its 52-week high on 01/05/23, shares of the company touched a low of $1.18 and a high of $71.40 in 52 weeks. It has reached a new high 2 times so far this year and achieved 25.07% or $0.85 in price. In spite of this, the price is down -94.06% from the 52-week high.
180 Life Sciences Corp. (ATNF) stock’s beta is 0.65. Other valuation ratios to consider include the price-to-book (PB) ratio at 0.32.
The quick ratio of 180 Life Sciences Corp. for the three months ended September 29 was 1.40, and the current ratio was 1.40, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.02 for the quarter ending September 29. Its gross profit as reported stood at $0.19 million compared to revenue of $15.64 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, 180 Life Sciences Corp.’s return on assets was -30.40%.
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$21.49 million in the quarter, while revenues of $2.94 million were grew 185.16%. The analyst consensus anticipated 180 Life Sciences Corp.’s latest quarter earnings to come in at $0.2 per share, but it turned out to be -$1.4, a -800.00% surprise. For the quarter, EBITDA amounted to $15.44 million. Shareholders own equity worth $2.02 million.
From a technical analysis perspective, let’s take a brief look at 180 Life Sciences Corp. (ATNF) price momentum. RSI 9-day as of the close on 25 January was 55.34%, suggesting the stock is Neutral, with historical volatility in this time frame at 207.05%.
As of today, ATNF’s price is $3.52 +19.10% or $0.68 from its 5-day moving average. ATNF is currently trading +241.94% higher than its 20-day SMA and -75.10% lower than its 100-day SMA. However, the stock’s current price level is -41.50% below the SMA50 and -90.41% below the SMA200.
The stochastic %K and %D were 12.09% and 16.78%, respectively, and the average true range (ATR) was 1.02. With the 14-day stochastic at 28.14% and the average true range at 1.13, the RSI (14) stands at 50.49%. The stock has reached -0.04 on the 9-day MACD Oscillator while the 14-day reading was at -0.38.
Maxim Group launched coverage on 180 Life Sciences Corp. (NASDAQ: ATNF) in its analyst report released on September 15, 2021. The firm assigned the stock a Buy rating. The consensus rating for 180 Life Sciences Corp. (ATNF) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell ATNF, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.
What is ATNF’s price target for the next 12 months?
Analysts predict a range of price targets between $4.00 and $4.00, with a median target of $4.00. Taking a look at these predictions, the average price target given by analysts for 180 Life Sciences Corp. (ATNF) stock is $4.00.